




API

Generics 2026

API Product List

	Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA		
1.	Acenocumarol		152-72-7	✓									
2.	Acetazolamide	Form II	59-66-5	✓	✓	✓		✓	✓			✓	
3.	Alendronate sodium	Trihydrate	121268-17-5	✓	✓	✓	✓	✓	✓	✓	P	✓	
4.	Aniracetam	Monoclinic form	72432-10-1	✓									
5.	Antazoline HCL		2508-72-7	✓									
6.	Antazoline mesylate		3131-32-6	✓									
7.	Antazoline sulfate	Crystalline form	24359-81-7	✓									
8.	Aripiprazole	Type I	129722-12-9	✓	✓	✓						✓	
9.	Aripiprazole monohydrate (non-sterile)	Monohydrate	851220-85-4	✓		✓							
10.	Baclofen	Anhydrous polymorphic form	1134-47-0	✓	✓	✓		✓	✓	✓	P	✓	
11.	Carbamazepine	Form III	298-46-4	✓	✓	✓			✓				
12.	Carvedilol	Form II	72956-09-3	✓	✓	✓		✓	✓				
13.	Carvedilol phosphate hemihydrate	Form I	610309-89-2	✓		✓							
14.	Clemastine fumarate		14976-57-9	✓	P								
15.	Cloпамide		636-54-4	✓									
16.	Disulfiram		97-77-8	✓	✓								
17.	Etodolac	Crystalline racemate, none	41340-25-4	✓	✓	✓		✓	✓	✓	✓		
18.	Hydrochlorothiazide	Form I	58-93-5	✓	✓	✓	✓	✓	✓	✓	P	✓	
19.	Ibandronate sodium	Monohydrate Form B	138926-19-9	✓	✓	✓	✓	✓	✓		P	✓	
20.	ITCL Denotivir		51287-57-1	✓									
21.	Lamotrigine	Anhydrous monoclinic	84057-84-1	✓	✓	✓	✓	✓	✓				
22.	Molsidomine		25717-80-0	✓	✓				✓				
23.	Nefopam Hydrochloride		23327-57-3	✓								✓	
24.	Opipramol dihydrochloride	Crystalline form	909-39-7	✓									
25.	Pentoxifylline	Form I	6493-05-6	✓	✓	✓	✓		✓			✓	
26.	Phenyl salicylate	Crystalline orthorhombic form	118-55-8	✓									
27.	Piracetam	Form II	7491-74-9	✓	✓						P	✓	
28.	Risedronate sodium 2.5-hydrate	Form A	329003-65-8	✓	✓	✓		✓	✓	✓	P		

P - pending

API Product List

	Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA	
29.	Rivaroxaban	Modification I	366789-02-8	✓	✓	✓	✓		✓	✓	✓	
30.	Salicylamide	Monoclinic form with space group I2/a	65-45-2	✓			P					
31.	Sildenafil citrate	Anhydrous Form	171599-83-0	✓	✓	✓	✓	✓				
32.	Sitagliptin hydrochloride	Form III	862156-92-1	✓		✓						
33.	Sodium salicylate	Monoclinic form (space group P2 ₁ /m)	54-21-7	✓		✓		✓				
34.	Tadalafil	Form A (form I)	171596-29-5	✓	✓	✓	✓	✓			P	
35.	Tolterodine tartrate	Crystalline Form I	124937-52-6	✓	✓		P			✓		
36.	Topiramate	Orthorhombic structure	97240-79-4	✓		✓			✓			
37.	Vardenafil hydrochloride	Trihydrate form	330808-88-3	✓	✓	✓	✓	✓	✓	✓		
38.	Xylometazoline HCl		1218-35-5	✓	✓		P					
39.	Zoledronic acid monohydrate	Form I	165800-06-6	✓	✓	✓		✓		✓	P	✓

P = pending

Disclaimer

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Oncology / HPAPI Developed & Pipeline

	Product	Polymorphic form	CAS No.	OEB	Samples	 DMF	 DMF	 DMF	 CADIFA
1.	Abemaciclib*	Form III	1231929-97-7	4	Available	✓	✓	P	P
2.	Enzalutamide	Anhydrous form R1	915087-33-1	3	Available	P	✓	P	P
3.	Palbociclib*	Crystal form A	571190-30-2	4	Available	✓	✓	P	P
4.	Talazoparib	Amorphous	1207456-01-6	6	Q4 2027				
5.	Trametinib dimethyl sulfoxide	Crystalline form	1187431-43-1	5	Available	✓	✓	P	P
6.	Vismodegib	Crystalline form I	879085-55-9	5	Available	✓	✓	P	P

* partnership with Egis

Developed API & Pipeline

	Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA
1.	Apixaban	Form N-1	503612-47-3	✓		✓			✓		P
2.	Apremilast	Form B	608141-41-9	✓		✓			✓	✓	
3.	Baricitinib	Form I	1187594-09-7	✓		✓			✓		
4.	Brexiprazole	Anhydrous form (form I)	913611-97-9	✓		✓					P
5.	Dapagliflozin	Amorphous	461432-26-8	✓		✓		✓	✓	✓	P
6.	Dapagliflozin Propanediol Monohydrate	Crystalline SC-3	960404-48-2	✓	P	✓					P
7.	Empagliflozin	Crystalline anhydrous	864070-44-0	✓		✓			✓	✓	P
8.	Isavuconazonium sulfate	Amorphous	946075-13-4	✓		✓					
9.	Nusinersen	Amorphous	1258984-36-9	2026		2026		2026			2026
10.	Pimavanserin tartrate	Crystalline anhydrous form C	706782-28-7	✓		✓					
11.	Risdiplam	Amorphous Crystalline Form A Crystalline Form E	1825352-65-5	2027		2027		2027			2027
12.	Sacubitril/Valsartan complex	Crystalline	936623-90-4	✓		✓					
13.	Safinamide methanesulfonate	Crystalline anhydrous form A1	202825-46-5	✓		✓			P		
14.	Ticagrelor	Form II	274693-27-5	✓	✓	✓			✓	✓	P

P - pending

Disclaimer

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).


Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

We are proud of our **70 years of experience** in supporting patients' health with **high quality APIs**



Hybrid Business Model

- ✓ **>70 years of experience in API business**
- ✓ **Generics and CDMO** From development to commercial
- ✓ **European location** R&D and 2 manufacturing plants
- ✓ **Agile organisation** Fast decision making, top execution
- ✓ **Project management excellence**
- ✓ **Global market presence**



Key Facts



>70
Products

>70
Countries



~455
(R&D ~70, ~16 PhD) Employees



Regulatory



Full value chain

R&D, commercial production,
supply chain, PMO

Main Technologies



High Potent

- ✓ **PDL R&D:**
OEB ≤ 6 (OEL $> 10\text{ng/m}^3$)
- ✓ **GMP PP/KL:**
OEB ≤ 5 (OEL $> 200\text{ng/m}^3$)
- ✓ **GMP Commercial:**
OEB ≤ 6 (OEL $> 10\text{ng/m}^3$)



Cryogenic


- ✓ **PP:** Reactor capacity range:
0.1 to 0.5 m³
Operational temperature:
down to -80°C
- ✓ **COMMERCIAL:** reactor capacity
range: 2.5 to 6.3m³
Total reactors vol: 23.5m³



Oligonucleotides

- ✓ GMP small scale production
line available
- ✓ First product validated by Q4 2025

EU-based CDMO and API manufacturer, trusted
by customers and business partners around the
world for 70+ years



**Polpharma Pharmaceutical
Works**

Pelplinska 19
83-200 Starogard Gdański
Poland

Contact:

+48 58 563 16 00

API CDMO

CDMO@polpharma.com

API Generics

API@polpharma.com



[Technical Capabilities Video](#)

Customer Service API

CS.API@polpharma.com

Customer Technical Service

techCS.API@polpharma.com



[Save the API product list](#)